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ABSTRACT
TALENs are important new tools for genome engin-
eering. Fusions of transcription activator-like (TAL)
effectors of plant pathogenic Xanthomonas spp. to
the FokI nuclease, TALENs bind and cleave DNA in
pairs. Binding specificity is determined by custom-
izable arrays of polymorphic amino acid repeats in
the TAL effectors. We present a method and
reagents for efficiently assembling TALEN con-
structs with custom repeat arrays. We also describe
design guidelines based on naturally occurring TAL
effectors and their binding sites. Using software that
applies these guidelines, in nine genes from plants,
animals and protists, we found candidate cleavage
sites on average every 35bp. Each of 15 sites
selected from this set was cleaved in a yeast-based
assay with TALEN pairs constructed with our re-
agents. We used two of the TALEN pairs to mutate
HPRT1 in human cells and ADH1 in Arabidopsis
thaliana protoplasts. Our reagents include a
plasmid construct for making custom TAL effectors
and one for TAL effector fusions to additional
proteins of interest. Using the former, we con-
structed de novo a functional analog of AvrHah1 of
Xanthomonas gardneri. The complete plasmid set is
available through the non-profit repository AddGene
and a web-based version of our software is freely
accessible online.
INTRODUCTION
Transcription activator-like (TAL) effectors are a newly
described class of speciﬁc DNA binding protein, so far
unique in the simplicity and manipulability of their target-
ing mechanism. Produced by plant pathogenic bacteria in
the genus Xanthomonas, the native function of these
proteins is to directly modulate host gene expression.
Upon delivery into host cells via the bacterial type III
secretion system, TAL effectors enter the nucleus, bind
to effector-speciﬁc sequences in host gene promoters and
activate transcription (1). Their targeting speciﬁcity is
determined by a central domain of tandem, 33–35 amino
acid repeats, followed by a single truncated repeat of 20
amino acids (Figure 1a). The majority of naturally
occurring TAL effectors examined have between 12 and
27 full repeats (2). Members of our group and another lab
independently discovered that a polymorphic pair of
adjacent residues at positions 12 and 13 in each repeat,
the ‘repeat-variable di-residue’ (RVD), speciﬁes the target,
one RVD to one nucleotide, with the four most common
RVDs each preferentially associating with one of the four
bases (Figure 1a) (3,4). Also, naturally occurring recogni-
tion sites are uniformly preceded by a T that is required
for TAL effector activity (3,4). These straightforward
sequence relationships allow the prediction of TAL
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effector responsive promoter elements (7), as well as cus-
tomization of TAL effector repeat domains to bind DNA
sequences of interest (8–11).
As a result, TAL effectors have attracted great interest
as DNA targeting tools. In particular, we and other
groups have shown that TAL effectors can be fused to
the catalytic domain of the FokI nuclease to create
targeted DNA double-strand breaks (DSBs) in vivo for
genome editing (8,10,12,13). Since FokI cleaves as a
dimer, these TAL effector nucleases (TALENs; 8)
function in pairs, binding opposing targets across a
spacer over which the FokI domains come together to
create the break (Figure 1b). DSBs are repaired in
nearly all cells by one of two highly conserved processes,
non-homologous end joining (NHEJ), which often results
in small insertions or deletions and can be harnessed for
gene disruption, and homologous recombination (HR),
which can be used for gene insertion or replacement
(14,15). Genome modiﬁcations based on both of these
pathways have been obtained with high frequency in a
variety of plant and animal species using zinc-ﬁnger nu-
cleases (ZFNs) and homing endonucleases. However, for
each of these platforms, engineering novel speciﬁcities has
generally required empirical and selection-based
approaches that can be time and resource intensive.
Despite a signiﬁcant recent advance for ZFNs that takes
ﬁnger context into account to achieve high success rates
(16), targeting capacity (the diversity of sequences that can
be recognized) still suffers limitations (17–19). TALENs
thus far appear not to be subject to these constraints. In at
least one study, mutagenesis frequency was estimated to
be as high as 25% of transfected cells, on par with or
better than ZFNs (10).
The TAL effector repeat domain also has been success-
fully customized to make targeted transcription factors,
both in plants in the native protein context and in
human cells with the TAL effector activation domain re-
placed by VP64 (9,11). Fusions to other protein domains
for chromatin modiﬁcation, gene regulation, or other
applications can also be envisioned. Thus, an efﬁcient
method for assembling genetic constructs to encode
TAL effectors and TAL effector fusions to other proteins,
with repeat arrays of user-deﬁned length and RVD
sequence, is highly desirable.
In our previous work, we constructed TALENs with
customized repeat arrays through sequential cloning of
sequence-veriﬁed single, double and triple repeat modules
(8). We sought a more rapid approach that would not rely
on commercial synthesis, which is expensive, or PCR-
based methods, which can result in mutations or recom-
bined repeats. We opted for Golden Gate cloning,
a recently developed method of assembling multiple
DNA fragments in an ordered fashion in a single reaction
(20,21). The Golden Gate method uses Type IIS restric-
tion endonucleases, which cleave outside their recogni-
tion sites to create unique 4bp overhangs (sticky ends)
(Figure 2). Cloning is expedited by digesting and ligating
in the same reaction mixture because correct assembly
eliminates the enzyme recognition site.
We report here a complete set of plasmids for
assembling novel repeat arrays for TALENs, TAL effect-
ors or TAL effector fusions to other proteins using the
Golden Gate method in two steps. We also describe
software for TALEN-targeting based on guidelines we de-
veloped to reﬂect naturally occurring TAL effector
binding sites and on our previous TALEN study. We
show that TALENs targeted with this software and con-
structed using the plasmid set are active in a yeast DNA
cleavage assay and effective in gene targeting in human
cells and Arabidopsis thaliana (hereafter Arabidopsis)
protoplasts. Finally, we demonstrate successful construc-
tion of a functional analog of the avrHah1 TAL effector
gene of Xanthomonas gardneri (22).
MATERIALS AND METHODS
Protocol for assembly of custom TALEN, TAL effector
or TAL effector fusion-ready constructs
Assembly of a custom TALEN or TAL effector construct
is accomplished in 5 days (Figure 3) and involves two
steps: (i) assembly of repeat modules into intermediary
arrays of 1–10 repeats and (ii) joining of the inter-
mediary arrays into a backbone to make the ﬁnal con-
struct. A schematic representation is shown in Figure 2
and the complete set of required plasmids is displayed in
Supplementary Figure S1. Construction and features of
the plasmids themselves are described in the following
section. The assembly protocol differs slightly for arrays
of 12–21 modules versus arrays of 22–31 modules. We use
an example here for construction of a TALEN monomer
with a 16 RVD array and note differences in the protocol
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Figure 1. TAL effector and TALEN structure. (a) Structure of a nat-
urally occurring TAL effector. A consensus repeat sequence is shown
with the repeat-variable di-residue (RVD) underlined. The sequence of
RVDs determines the target nucleotide sequence. The four most
common RVDs, on which our designs and plasmids are based, are
shown with their most frequently associated nucleotide. Some
evidence suggests that the less common RVD NK (not displayed) has
greater speciﬁcity for G than NN does and for that reason our plasmid
set also includes NK modules. (b) Structure of a TALEN. Two mono-
meric TALENs are required to bind the target site to enable FokI to
dimerize and cleave DNA. NLS, nuclear localization signal(s); AD,
transcriptional activation domain; B, BamHI; S, SphI.
e82 Nucleic Acids Research, 2011,Vol. 39,No. 12 PAGE 2 OF 11Figure 2. Golden Gate assembly of custom TAL effector and TALEN constructs using module, array, last repeat and backbone plasmids. By using
the type IIS restriction endonucleases BsaI and Esp3I, modules containing the desired RVDs can be released with unique cohesive ends for ordered,
single-reaction assembly into array plasmids in a ﬁrst step, and those arrays subsequently released and assembled in order in a second step into a
backbone plasmid to create full length constructs with custom repeat arrays (see text for details). NLS, nuclear localization signal(s); AD, tran-
scriptional activation domain; tet, tetracycline resistance; spec, spectinomycin resistance; amp, ampicillin resistance; attL1 and attL2, recombination
sites for Gateway cloning; B, BamHI, and S, SphI, useful for subcloning custom repeat arrays. Unique restriction enzyme sites ﬂanking the coding
sequences, useful for subcloning the entire constructs into other vectors, are not shown but can be found in the sequence ﬁles (Supplementary Data).
Figure 3. TALEN or TAL effector construct assembly timeline.
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Day 1. Consider the RVD array NI HD HD NN HD
NI NI NG HD NG HD NI NI NG HD NG, targeting the
sequence 50-AGCCCAATCTCACTCT-30. Note that the
50-T preceding the RVD-speciﬁed sequence is not shown
and need not be considered in the assembly, although
based on evidence to date (3,4), it should be considered
during site selection. Select from the module plasmids
those that encode RVDs 1–10 in the array using plasmids
numbered in that order. For example, the plasmid for the
ﬁrst RVD would be pNI1, the second pHD2, the third
pHD3, etc. Modules from these plasmids will be cloned
into array plasmid pFUS_A. Next, select modules for
RVDs 11–15 in the 16 RVD array again starting with plas-
mids numbered from 1. Thus for RVD 11 pHD1 would be
used, for RVD 12 pNI2, etc. Note that the 16th and last
RVD is encoded by a different, last repeat plasmid and is
added later, in the second step (see Day 3). Modules
encoding RVDs 11–15 are cloned into a pFUS_B array
plasmid. The pFUS_B plasmids are numbered 1–10 and
should be selected according to the number of modules
going in. Thus, in our example, pFUS_B5 should be
used. If arrays of 22–31 modules are to be assembled,
the ﬁrst 10 modules are cloned into pFUS_A30A, the
second 10 modules into pFUS_A30B and the remaining
modules into the appropriate pFUS_B plasmid, again
according to the number of modules going in.
The module and array plasmids (150ng each) are sub-
jected to digestion and ligation in a single 20ml reaction
containing 1ml BsaI (10U, New England BioLabs) and
1ml T4 DNA Ligase (2000U, New England BioLabs) in
T4 DNA ligase buffer (New England BioLabs). The
reaction is incubated in a thermocycler for 10 cycles of
5min at 37 C and 10min at 16 C, then heated to 50 C
for 5min and then 80 C for 5min. Then, 1ml 25mM ATP
and 1ml Plasmid Safe DNase (10U, Epicentre) are added.
The mixture is incubated at 37 C for 1h, then used to
transform Escherichia coli cells. Cells are plated on LB
agar containing 50mg/ml spectinomycin, with X-gal and
IPTG for blue/white screening of recombinants, as des-
cribed (23). Treatment with Plasmid Safe DNase is an
important step to prevent linear DNA fragments,
including partial arrays, from recombining into and cir-
cularizing the linearized array plasmids following trans-
formation, due to the presence of partial repeat
sequences at the termini of the array plasmids.
Day 2. Pick up to three white colonies from each trans-
formation and start overnight cultures.
Day 3. Isolate plasmid DNA and identify clones with
the correct arrays by restriction enzyme digestion and
agarose gel electrophoresis. AﬂII and XbaI will release
the repeat arrays, which will be 1048bp for pFUS_A,
1052 for pFUS_A30A, 1040 for pFUS_A30B and of
varying sizes for pFUS_B plasmids.
The next step is to join the intermediary arrays, along
with a last repeat, into the desired context, using one of
the four backbone plasmids. A 20ml digestion and liga-
tion reaction mixture is prepared as in the ﬁrst step, but
with 150ng each of the pFUS_A and pFUS_B plas-
mids containing the intermediary repeat arrays (or the
pFUS_A30A, pFUS_A30B and pFUS_B plasmids
carrying the intermediaries for ﬁnal arrays of 22–31
RVDs), 150ng of the backbone plasmid, in this case
pTAL3 or pTAL4 for constructing a TALEN monomer,
and importantly, 150ng of the appropriate last repeat
plasmid. In our example, pLR-NG, for the 16th and last
RVD, would be used. The reaction is treated and used to
transform E. coli as above, except that Plasmid Safe
DNAse treatment is omitted because the backbone
plasmid termini have no homology with the array. Also,
in this step, ampicillin (100mg/ml) is used in place of spec-
tinomycin for selection of transformants.
Day 4. Pick up to three white colonies from each trans-
formation and start overnight cultures.
Day 5. Isolate plasmid DNA and identify clones con-
taining the ﬁnal, full-length repeat array. Array length can
be veriﬁed by digestion with BstAPI (or StuI) and AatII,
which cut just outside the repeats, or with SphI, which
cuts farther out. Array integrity can be checked using
BspEI, which cuts only in HD modules 2–10. The array
can also be characterized by DNA sequencing.
Construction of module, last repeat, array and backbone
plasmids
Repeat modules with the RVDs HD, NG, NI, NK and
NN, across 10 staggered positions and with a BsaI site
added to each end, were synthesized. The modules were
cloned between the unique XbaI and XhoI sites of pTC14,
replacing the spectinomycin resistance gene in that
plasmid, to create a set of 50 module plasmids (pHD1
through pHD10, pNG1 through pNG10, etc.). pTC14 is
a derivative of the Gateway entry and TOPO cloning
vector pCR8 (Invitrogen) in which the Gateway cassette
was replaced with a gene for tetracycline resistance using
the ﬂanking EcoRV and HpaI sites. Aside from the RVD
codons, the modules at each position are identical, except
for a BspEI site introduced into HD modules 2–10
for testing full-length array integrity by digestion. The
modules are based on the ﬁrst repeat of tal1c of X. oryzae
pv. oryzicola strain BLS256 (3), which matches the
consensus repeat and is made up of common codons.
Similarly, one module for each of the ﬁve RVDs con-
taining the last, truncated repeat of the TAL effector
repeat domain was synthesized and cloned in plasmid
pCR8 (carrying the spectinomycin resistance gene) using
ApaI and XbaI and replacing the Gateway cassette, to
create ﬁve last repeat plasmids (e.g. pLR-HD).
Next, array plasmids pFUS_A, pFUS_A30A and
pFUS_A30B were created by cloning, using AﬂII and
XbaI, synthesized fragments into pCR8 that contain two
internal BsaI sites oriented to cut outward into ﬂanking
sequences such that linearizing the vector with the enzyme
leaves the appropriate overhangs to accept an array of 10
repeat modules (i.e. complementary on one side to the
50-end of position 1 modules and on the other to the
30-end of position 10 modules). The series of array
plasmids pFUS_B1 through pFUSB10 were made simi-
larly to be complementary on one side to the 50-end of
position 1 modules, but complementary on the other to
the 30-end of modules in position 1–10, respectively, to
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fragment containing the lacZ gene for blue/white
screening (23) was cloned between the two BsaI sites.
For this, the multiple cloning sites between the HincII
and Eco53kI sites in phagemid pBCSK+ (Stratagene)
was deleted and the lacZ gene PCR ampliﬁed with primers
carrying KasI and AgeI overhangs. These sites were
included in the synthesized fragments, allowing the lacZ
gene to be placed between the BsaI sites, maintaining the
overhang sequences for accepting modules. The inserts in
the array plasmids all contain terminal Esp3I (another
type IIS enzyme) sites positioned to cut inward and
release the arrays with appropriate overhangs for
ordered ligation into a backbone plasmid for complete
arrays of 12–21 (a pFUS_A array with a pFUS_B array,
plus a last repeat) or 22–31 repeats (a pFUS_A30A with a
pFUS_A30B and a pFUS_B array, plus a last repeat).
These sites, or ﬂanking AﬂII and XbaI sites in the
vector (enzymes that are generally less expensive), can
also be used to screen assembled clones for the correct
size.
Backbone plasmid pTAL3 was derived from pFZ85, a
precursor to the TALEN yeast expression vector we
created previously (8). Derived from pDW1789 (24),
pFZ85 contains the counter-selectable ccdB gene ﬂanked
by BamHI sites downstream of the yeast TEF promoter
and a sequence encoding a nuclear localization signal and
upstream of a sequence encoding a linker and the FokI
nuclease catalytic domain. For our previous TALEN con-
structs, we used tal1c as a context for custom repeat
arrays. First, solely for expediency of later adding the
lacZ gene, the SphI fragment of tal1c was replaced with
the SphI fragment of TAL effector gene pthXo1 (25),
which has minor polymorphisms ﬂanking the repeat
region that create convenient restriction enzyme sites.
The spanning BamHI fragment of the resulting gene was
then cloned between the BamHI sites of pFZ85. Finally,
the repeat region within the SphI fragment was deleted by
digestion with BstAPI and AatII and replaced with a
fragment carrying the lacZ gene for blue/white screening
(cloned into this fragment as described above), ﬂanked by
outward cutting Esp3I sites and the necessary sequences to
create a speciﬁc overhang on either end to accept ﬁnal
arrays and reconstitute a complete TAL effector
domain. Importantly, the SphI sites, which are highly
conserved among TAL effectors and are useful for
swapping the entire repeat region into other TAL
effector constructs, are preserved. The architecture of
the constructs is the same as reported in our earlier
work (8), encoding 287 and 230 amino acids of the TAL
effector upstream and downstream of the repeats, respect-
ively, with an additional six amino acids linking the TAL
effector and FokI domains. To create pTAL4, which is
identical to pTAL3 except that it carries LEU2 in place
of HIS3, ﬁrst the LEU2 gene was PCR ampliﬁed using
primers having 20bp extensions with homology to the
region at the 50-end of the Bpu10I and 30-end of the
AfeI site in pDW1789. Then, pDW1789 was linearized
with Bpu10I and AfeI (removing the HIS3 gene) and the
PCR-ampliﬁed LEU2 gene was inserted by in vivo recom-
bination in E. coli (26). Finally, into this plasmid, the
XbaI–SacI fragment of pTAL3 containing the TALEN
backbone construct was introduced at the corresponding
sites.
pTAL1 was created by replacing the SphI fragment of
tal1C in pCS691 with the corresponding SphI fragment of
pTAL3, containing the lacZ gene and the Esp3I sites and
ﬂanking sequences for accepting ﬁnal arrays. pCS691 is a
derivative of Gateway entry vector pENTR-D
(Invitrogen) containing between the attL sites, the
complete tal1c gene preceded by both Kozak and Shine–
Dalgarno consensus sequences for efﬁcient translation in
eukaryotic or bacterial cells, respectively. In pCS691, the
kanamycin resistance gene of pENTR-D is replaced by the
BspHI fragment of pBlueScript SK(-) (Stratagene) for
ampicillin resistance. To create pTAL2, the stop codon
of tal1c in pTAL1 was deleted using the QuickChange
mutagenesis kit (Stratagene) to allow translational fusion
to other protein domains following Gateway recombin-
ation into a destination vector.
A schematic representation of all modules, last repeat,
array and backbone plasmids (Supplementary Figure S1)
and a folder containing complete sequences are included
in Supplementary Data.
Software to identify candidate TALEN target sites
The software used to design TALENs in this study was
written in Python 2.6.4. and runs in Linux (Ubuntu 10.10).
It is available for use as an online tool (TAL
Effector-Nucleotide Targeter, TALE-NT; http://boglabx.
plp.iastate.edu/TALENT/). The tool provides a window
to input DNA sequences (Supplementary Figure S2a),
which are then scanned for sites based on TALEN
design guidelines we established, described in the
‘Results’ section. The software identiﬁes sets of TALEN
recognition sites between 15 and 30bp in length and
separated by a spacer. The default spacer lengths are
15bp and 18–30bp (8), but other lengths can be speciﬁed
by the user. In addition, buttons allow users to exclude
design guidelines individually. The output is tab-delimited
text, which can be imported into standard spreadsheet
software (Supplementary Figure S2b). It provides coord-
inates and sequences of identiﬁed targets indicating the
recognition sites for the left and right TALEN
monomers and the spacer sequence. Since naturally
occurring TAL effector recognition sites are uniformly
preceded by a T, which is required for TAL effector
activity (3,4), only TALEN monomer recognition sites
preceded by a T are included. The T itself is not part of
the output. Finally, the software provides the RVD se-
quences needed to construct the corresponding custom
TALENs.
Testing TALEN function in yeast
The yeast assay for TALEN function was adapted from
one we developed previously for ZFNs (8,24) in which
cleavage of the target, positioned between partially
duplicated fragments of the lacZ gene, reconstitutes the
gene via subsequent recombination to provide a quantita-
tive readout (Supplementary Figure S3a). For typical
heterodimeric target sites (i.e. such as would typically
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structs, in pTAL3 and pTAL4, are transformed together
into yeast strain YPH500 (a mating type) using histidine
and leucine prototrophy for selection. Individual TALEN
monomers can be tested on homodimeric sites using just
one of these plasmids. The target is made using
synthesized complementary oligonucleotides that
produce BglII- and SpeI-compatible ends and cloned be-
tween the lacZ fragments in the high copy DNA cleavage
reporter plasmid pCP5 (24) cut with those enzymes
(Supplementary Figure S3b). The target plasmid is trans-
formed into yeast strain YPH499 (a mating type), using
tryptophan prototrophy for selection, but also excluding
uracil from the growth medium: in addition to the target
cloning site, pCP5 carries also the URA3 gene between the
lacZ fragments so that selection for URA3 ensures that the
strain has not undergone spontaneous recombination (and
loss of URA3) prior to the assay.
Three transformants each of YPH500 carrying the
TALEN construct(s) and of YPH499 carrying the target
plasmid are cultured overnight at 30 C, with rotary
shaking at 800rpm, in synthetic complete medium lack-
ing histidine and/or leucine (TALENs) or tryptophan and
uracil (target). TALEN and target transformants are next
mated (three pairs) by combining 200–500ml of the over-
night cultures, adding 1ml of YPD medium and incubat-
ing for 4–6h at 30 C, shaking at 250–300rpm. Cells are
harvested by centrifguation, washed in 1ml synthetic
complete medium lacking histidine and/or leucine and
tryptophan, but now containing uracil, then resuspended
in 5ml of that medium and incubated overnight again at
30 C, with shaking (800rpm), to an OD600 between 0.1
and 0.9. Cells are harvested by centrifugation, then resus-
pended and lysed using YeastBuster Protein Extraction
Reagent (Novagen) according to the manufacturer’s
protocol for small cultures. A total of 100ml of lysate is
transferred to a microtiter well plate and b-galactosidase
activity measured and normalized as previously described
(24). For high-throughput, yeast may be cultured and
mated (using a gas permeable seal) as well as lysed in
24-well blocks. We typically express activity relative to a
Zif268 ZFN (24).
Expression of custom TALENs in human cells and
Arabidopsis protoplasts and detection of site-speciﬁc
mutations
One of the pairs of TALENs targeting the human HPRT1
gene was subcloned into the mammalian expression vector
pCDNA3.1(-) (Invitrogen) using XhoI and AﬂII. These
enzymes excise the entire TALEN from pTAL3 or
pTAL4 and place the coding sequence under control of
the CMV (cytomegalovirus) promoter. The resulting
plasmids were introduced into HEK293T cells by trans-
fection using Lipofectamine 2000 (Invitrogen) following
the manufacturer’s protocol. Cells were collected 72h
after transfection and genomic DNA isolated and
digested with Hpy188I, which cuts in the spacer
sequence of the TALEN target site. After digestion, a
chromosomal fragment encompassing the target site was
ampliﬁed by PCR. Upon completion, the reactions were
incubated for 20min at 72 C with 4ml of Taq DNA poly-
merase. PCR products then were digested with Hpy188I
and cloned in a TOPO TA vector (Invitrogen).
Independent clones containing the full-length PCR
product were sequenced to evaluate mutations at the
cleavage site.
The TALENs targeting the Arabidopsis ADH1 gene
were subcloned into the plant expression vector pFZ14
(27) using XbaI and SacI. These enzymes excise the
entire TALEN from pTAL3 or pTAL4 and place the
coding sequence under control of the CaMV (cauliﬂower
mosaic virus) 35S promoter. Recombinant plasmids were
transformed into Arabidopsis protoplasts as previously
described (27). Forty-eight hours after transformation,
DNA was prepared and digested with PﬂFI, which cuts
in the spacer sequence of the TALEN target site. After
digestion, a chromosomal fragment encompassing the tar-
get site was ampliﬁed by PCR and the reaction products
were once again digested with PﬂFI and run on an agarose
gel. The band corresponding in size to undigested product
was excised and cloned and individual clones were
sequenced to evaluate mutations at the cleavage site.
Expression of a custom TAL effector in Xanthomonas and
in planta activity assay
An analog of avrHah1 was assembled into pTAL1 using
the Golden Gate method with HD, NI, NG and NN
modules, ordered to match the AvrHah1 binding site in
the promoter of the Bs3 gene (22). A native avrHah1 con-
struct was made by replacing the BamHI fragment of tal1c
in pCS495 with that of avrHah1. pCS495 is tal1c preceded
by Shine–Dalgarno and Kozak consensus sequences in
pENTR-D (Invitrogen). The analog and native avrHah1
constructs and tal1c were moved into pKEB31 by
Gateway cloning (LR reaction). pKEB31 is a derivative
of pDD62 (28) that contains a Gateway destination vector
cassette (Invitrogen) between the XbaI and BamHI sites
and a tetracycline resistance gene in place of the gene
for gentamycin resistance. The resulting plasmids were
introduced into X. campestris pv. vesicatoria strain
85–10 by electroporation and transformants were inocu-
lated to 6-week-old pepper plants by syringe inﬁltration,
as described (22). After 48h, inﬁltrated leaves were cleared
in 70% ethanol and 10% glycerol and photographed.
RESULTS
Efﬁcient assembly of custom repeat arrays into TALEN
and other TAL effector-based constructs
Our implementation of the Golden Gate method accom-
plishes custom TAL effector construct assembly in two
steps (Figure 2 and Supplementary Figure S1). In the
ﬁrst step, it uses ﬁve sets of 10 staggered repeat clones,
one for each of the four most common RVDs HD, NI,
NG and NN, which associate most frequently with C, A,
T and G, respectively and one for the less common NK,
which at least in some contexts appears to have higher
speciﬁcity for G than NN does (9,10). Inserts in these
‘module’ plasmids carrying the desired RVDs are
released and assembled in order in one or two sets of 10
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enzyme. In the second step, the resulting array fragments
are joined, along with a ﬁnal, truncated repeat from a
collection of ﬁve ‘last repeat’ plasmids (one for each
RVD), into any of four different ‘backbone’ plasmids,
using a different type IIS enzyme, for a ﬁnal array of 12
(10+1+the last) to 31 (10+10+10+the last) RVDs.
Counting the 50-T that precedes the RVD speciﬁed se-
quences in TAL effector binding sites, the corresponding
target ranges from 13 to 32nt.
The backbone plasmids include (i) pTAL1 for assembl-
ing a custom TAL effector gene preceded by Shine–
Dalgarno and Kozak sequences for efﬁcient translation
in bacteria and eukaryotes, respectively, (ii) pTAL2, iden-
tical to pTAL1, but without a stop codon so that the
effector can be fused to other protein domains,
(iii) pTAL3 for assembling a custom TALEN and express-
ing it in yeast using the selectable marker HIS3 and
(iv) pTAL4, identical to pTAL3 but containing the
marker LEU2, so that two TALEN monomers can be
paired in the yeast assay (see subsequently). The TAL
effector constructs are ﬂanked by attL sites for transfer
by Gateway recombination (Invitrogen) into destination
vectors of choice. The TALEN constructs, though not
Gateway compatible, are ﬂanked by restriction enzyme
sites convenient for subcloning into different expression
vectors. All constructs retain the internal SphI sites
ﬂanking the repeat domain as well as the BamHI sites
farther out that are conserved in most TAL effectors
and can be used to readily swap a custom array into
other TAL effector-based constructs.
All of the array and backbone plasmids contain within
the cloning site the lacZ gene for blue/white screening to
identify recombinants (23). For the work presented here,
we successfully assembled >30 custom TALENs
(Supplementary Table S1) and one custom TAL effector,
ranging in array length from 15 to 30 RVDs. We never
failed to obtain the correctly assembled array plasmid
clone or the correctly assembled, ﬁnal backbone plasmid
clone for any of these by screening only three white
colonies per cloning reaction transformed into E. coli.
We routinely pick just two colonies and usually both are
correct (not shown). Assembly of one or more constructs
takes just 5 days (Figure 3 and refer ‘Materials and
Methods’ section).
Guidelines and software for TALEN site selection and
repeat array design
To facilitate TALEN design for genome editing, we wrote
a computer program that analyzes DNA sequences,
identiﬁes suitable, paired and opposing TAL effector
target sites across a spacer and generates corresponding
RVD sequences using the four most common RVDs (see
‘Materials and Methods’ section). The software uses
guidelines for TAL effector targeting that reﬂect naturally
occurring TAL effectors and their binding sites and spacer
lengths that we observed to function well in our previous
study using TALENs derived from naturally-occurring
TAL effectors (8). We established the targeting guidelines
by examining the 20 TAL effector-target pairs identiﬁed
by Moscou and Bogdanove (3). We looked for positional
biases, neighbor effects and overall trends in nucleotide
and RVD composition. To examine position effects for
sequences of different lengths, we conﬁned the analysis
to the ﬁve positions at either end. We compared
observed nucleotide and RVD frequencies to expected
frequencies, taken as the frequencies in the entire set of
sequences (Figure 4). The binding sites showed a strong
bias against T at position 1 (50-end), a bias against A at
position 2, biases against G at the last (30) and next-to-last
positions and a moderate bias for T at the last position.
RVD sequences showed corresponding positional biases:
NG was disfavored at position 1; NI was disfavored at
position 2 and NG was favored and NN disfavored at the
last position. The bias for NG at the last position was
particularly striking: NG occurs at this position in 85%
of the sequences compared to its overall observed fre-
quency of 18%. No neighbor effects were detected in the
binding sites or RVD sequences. Average nucleotide com-
position of the binding sites was 31±16% A, 37±13% C,
9±8% G, and 22±10% T. To expand on this dataset, we
used the weight matrix developed by Moscou and
Bogdanove (3) to identify the best-scoring binding sites
(preceded by a T) for each of 41 X. oryzae TAL effectors
in each of approximately 57000 rice promoters. We
retained those in genes shown by microarray analysis
(www.plexdb.org, experiment OS3) to be up-regulated
during infection. This analysis yielded close to 100
putative additional TAL effector–target pairs. These re-
ﬂected the same positional biases (data not shown). The
guidelines are therefore as follows: (i) As noted previously
for TAL effector binding sites (3,4), TALEN monomer
binding sites should be preceded by a 50-T, (ii) they
should not have a T at position 1, (iii) they should not
have an A at position 2, (iv) they should end with a T, so
that the corresponding TALENs will reﬂect the strong
bias for NG at this position and (v) they should have a
base composition within two standard deviations of the
averages we observed.
We did not systematically test the guidelines, but data
from intermediate constructs we obtained while build-
ing full-length TALENs with our earlier sequential
ligation method provide some support (Supplementary
Figure 4. Nucleotide and RVD frequencies at the termini of 20 target
and TAL effector pairs. RVDs that have a frequency of  20% at one
or more of the positions are shown. ‘XX’ represents all other RVDs.
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pairs showing no detectable activity in the yeast assay for
DNA cleavage (8), one did not match overall target nu-
cleotide composition, one did not have an RVD sequence
ending in NG and another did not meet either of these
guidelines. Two out of seven with activity <25% of the
Zif268 ZFN used as a control did not match overall target
nucleotide composition. One of four with activity 25–50%
of Zif268 did not have an RVD sequence ending in NG.
TALENs with 50% or greater activity of Zif268 met all of
the guidelines. The impact of the number of repeats in a
TALEN was also considered. In general, longer TALENs
that met all of the guidelines or medium-length TALENs
that met all guidelines and had a high percentage of HDs
showed the highest activity. Longer TALENs that failed
to meet one or more guidelines showed reduced activity
when compared to those of the same length that met all
guidelines. Thus, in addition to providing preliminary
support for the guidelines, the results also suggest that
array length positively correlates with activity.
Toward validating our method for making custom TAL
effector arrays, we used the software to ﬁrst identify can-
didate TALEN sites in seven plant (Arabidopsis, tobacco),
animal (human, zebraﬁsh, Drosophila) and protist
(Plasmodium) genes as well as in GFP and eGFP. In
these genes, the software found unique TALEN sites on
average every 35bp (range=15–120bp).
Activity of custom TALENs in a yeast-based DNA
cleavage assay
Custom TALEN pairs for 15 target sites (30 TALENs
total; Supplementary Table S1) were made using the
Golden Gate method and plasmids described above and
tested in the yeast-based DNA cleavage assay we
described previously (8). All TALEN pairs showed signiﬁ-
cant activity above the target-only negative controls and
14 of 15 showed activity  25% of our positive control, a
Zif268 ZFN (Figure 5). We have generally found for
ZFNs that this level of activity is sufﬁcient for targeted
mutagenesis of endogenous plant loci (24,27).
Targeted mutagenesis in human cells and Arabidopsis
protoplasts using custom TALENs
To validate the activity of our custom TALENs outside of
yeast, we used one of the TALEN pairs for the human
HPRT1 gene (HPRT1 B in Figure 5) and the TALEN pair
for the Arabidopsis ADH1 gene to carry out targeted mu-
tagenesis in human embryonic kidney cells and
Arabidopsis protoplasts, respectively. In both cases the
custom TALENs generated mutations at the recognition
site through imprecise repair of the cleaved chromosomes
by NHEJ (Figure 6). Our method of detection used an
enrichment step, so it was not possible to quantify muta-
genesis frequency. However, we obtained for HPRT1, 17
independent mutations including two single base pair sub-
stitutions and deletions ranging from 1–27bp roughly
centered on the spacer and for ADH1, 6 independent mu-
tations consisting of deletions ranging from 4 to 15bp,
also centered on the spacer.
Replication of AvrHah1 TAL effector activity with a
Golden Gate assembled clone
To assess our plasmids for construction of custom TAL
effectors, we assembled an analog of the avrHah1 TAL
effector gene of X. gardneri, which elicits a hypersensitive
reaction in pepper by transcriptionally activating the Bs3
resistance gene (22). We chose AvrHah1 because it is
highly divergent relative to other characterized TAL ef-
fectors, carrying predominantly 35 amino acid repeats (in
contrast to the more common 34 amino acid repeat on
which our modules are based) as well as other deviations
from the consensus sequences both within and outside the
repeat region. Introduced into X. campestris pv.
vesicatoria strain 85–10, which lacks AvrHah1, that was
then inoculated into pepper leaves, the Golden Gate
assembled clone triggered a Bs3 speciﬁc hypersensitive
reaction indistinguishable from that elicited by the
native effector (Figure 7). This recreation of AvrHah1
speciﬁcity using our modular reagents demonstrates their
utility for making custom transcription factors and under-
scores the sufﬁciency of the RVD sequences for targeting.
DISCUSSION
The hallmark feature of TAL effectors that makes them
such remarkably powerful tools for DNA targeting, their
Figure 5. Activity of 15 custom TALEN pairs targeting diverse se-
quences in a reporter-based yeast assay. TALENS were targeted to
gene sequences from the indicated organisms and to GFP and eGFP
using the software and constructed using the Golden Gate method and
plasmids described in the text. Activity was measured in a yeast-based
assay in which cleavage and recombination reconstitutes a functional
lacZ gene (see text for details). Activity was normalized to a Zif268
ZFN positive control. Activity of target-only controls for each is
plotted above the target-plus-TALEN values; in each case the activity
was undetectable. Error bars denote s.d.; n=3.
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cleotides in the recognition site in a straightforward and
modular fashion, also makes them challenging to
engineer. Commercial synthesis is effective (10) but expen-
sive. PCR-based methods (11) carry the risk of artifact
and recombination. Assembly by sequential ligation of
sequence-veriﬁed modules (8) is inexpensive and assures
array integrity, but is time consuming. The Golden Gate
method using the reagents we describe here, provides a
cost-effective, robust and rapid solution. TAL effector
constructs with arrays of up to 31 RVDs are assembled
in just two cloning steps using a set of sequence-veriﬁed
modules. Furthermore, the reagents provide great ﬂexibil-
ity for cloning arrays in different contexts and expressing
them in different organisms, either in our set of backbone
plasmids for TALENs, TAL effectors, or TAL effector
fusions to additional proteins, or by simple subcloning
or Gateway recombination into other vectors.
Zhang et al. (11) recently presented a protocol and set of
templates for Golden Gate-like assembly that involves
PCR ampliﬁcation of modules, intermediary arrays and
full-length arrays to yield TAL effector DNA binding
domains with 13 RVDs fused in a backbone vector to
VP64 (see also www.taleffectors.com). This marked a sig-
niﬁcant advance that enabled the authors to rapidly
assemble custom arrays and demonstrate the utility of
TAL effector-based proteins as custom transcription
factors to activate endogenous genes in human cells.
However, the method and plasmids we describe here
offer more versatility for broader utility, not only with
regard to the available contexts and portability of the
arrays, as noted above, but also in array length. The
ability with our reagents to construct arrays ranging
from 12 to 31 RVDs allows ﬁne-tuning for targeting and
will be important for testing the important outstanding
question of the relationship of length to afﬁnity and spe-
ciﬁcity. The broad range in array length also offers greater
ﬂexibility to systematically address other important ques-
tions including the contributions of individual RVD–nu-
cleotide associations to afﬁnity and speciﬁcity, as well as
the effect of position on mismatch tolerance (1). This
could be accomplished, e.g. by starting with an array of
minimal functional length and comparing the effects of
adding or interspersing additional RVDs aligned to differ-
ent nucleotides in the target.
Our method has the technical advantage of involving no
PCR. Although the Zhang et al. (11) repeat templates for
Figure 6. Site-directed mutagenesis in human embryonic kidney cells
and Arabidopsis protoplasts using custom TALENs. TALENs
targeted to the human HPRT1 gene (pair HPRT1 B in Figure 5) and
the Arabidopsis ADH1 gene (Figure 5) were transiently expressed in
human embryonic kidney cells and in Arabidopsis protoplasts, respect-
ively and the targets subsequently ampliﬁed and sequenced (see text for
details). Prior to ampliﬁcation, genomic DNA was digested with a re-
striction endonuclease having a site present in the TALEN target site to
reduce ampliﬁcation of wild-type sequences and enrich the amplicon
pool for mutated ones. Results for HPRT1 are shown in (a) and
ADH1 in (b). For each, the schematic at the top shows the chromo-
somal locus, short arrows designate primers used for PCR ampliﬁcation
following TALEN transient expression, sequence of the wild-type gene
(top line) and unique mutated alleles obtained are shown below,
binding sites for the TALEN monomers are underlined and the coin-
cident restriction endonuclease site is indicated.
2
1
2
3
1
3
ECW30R ECW
1 1
Figure 7. Activity of an AvrHah1 analog created using the Golden
Gate method and our plasmid set. Shown are leaves of pepper varieties
ECW30R, carrying the Bs3 resistance gene and ECW, lacking it, 48h
following spot-inﬁltration with suspensions of X. campestris pv.
vesicatoria strain 85–10 transformed to deliver (1) Tal1c (the effector
used to make the backbone plasmids in this study), (2) native AvrHah1
or (3) an AvrHah1 analog encoded by a construct made using the
Golden Gate method and our plasmid set. Leaves were cleared with
ethanol to reveal the accumulation of phenolic compounds, visible as
dark stained areas, indicative of the hypersensitive reaction induced by
TAL effector driven transcriptional activation of Bs3.
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slippage and inter-repeat recombination during PCR amp-
liﬁcation, this strategy does not prevent recombination
between repeats carrying the same RVD, particularly if
they are present in tandem. Also, in part because our
method involves no PCR, though it is 2 days longer, it
is less labor-intensive and time consuming day to day.
Though all of the custom arrays made for this study use
just the four most common RVDs, our plasmid set
includes modules with NK, which users might opt to sub-
stitute for NN to specify G, because NN sometimes asso-
ciates with A. We note however, based on data presented
by Miller et al. (Figure 2e in ref. 10), that NK also asso-
ciates substantially with A in some contexts. Modules with
yet additional RVDs can be generated readily by muta-
genesis of an existing set.
Among the genes we selected for targeting with
TALENs, we deliberately chose some for which targeting
with ZFNs has proven difﬁcult. For example, one of the
most common mutations in patients with cystic ﬁbrosis is
a deletion of 3nt (DF508) in CFTR; however, best efforts
to engineer a ZFN for this position only succeeded in
targeting a site >120bp away, a distance that would
likely compromise gene targeting efﬁciency (18). For our
CFTR TALENs, the DF508 mutation resides within the
spacer sequence at the site of TALEN cleavage. Similarly,
we previously created herbicide resistant tobacco plants by
gene targeting with ZFNs that recognize and cleave the
acetolactate synthase gene (24). The nearest ZFN that
could be engineered to the desired site of modiﬁcation
was 188bp away, whereas our TALENs cleave within
10bp of the desired sequence modiﬁcation. Finally,
AT-rich sequences have been difﬁcult to target with
ZFNs; we successfully targeted two sites in the AT-rich
(75.5%) Plasmepsin V gene of Plasmodium falciparum,
which has an overall genome content of 80.6% AT (29).
Generally, the high success rate of TALENs designed
using our software, which found sites in diverse sequences
on average every 35bp, suggests that targetability of
TALENs will prove superior to the public ZFN platforms,
which are estimated to be capable of targeting on average
every 500bp (16,18). Indeed, we anticipate our estimate of
targeting range is conservative, as some TALENs that do
not follow our design principles still recognize and cleave
DNA efﬁciently (10; Supplementary Table S2).
Activity varied among the TALENs we tested in the
yeast assay. The reason for this is not clear. It could
relate to expression levels or variability in the assay
itself, but more likely, the data reﬂect inherent differences
in the DNA binding afﬁnity of the arrays, possibly related
to their length and composition. The relationship of array
length and composition to overall afﬁnity is still an open
question that must be addressed. The important conclu-
sion for this study is that all of the TALENs were active,
demonstrating that the targeting approach as well as the
Golden Gate methods and plasmids for assembly are
robust. Our results in Arabidopsis protoplasts and
human cells, along with recent results from other groups
(10,13), indicate that TALENs are likely to be broadly
effective for genome engineering.
We have deposited all of our plasmids for constructing
and expressing TALENs as well as TAL effectors with
or without a stop codon in the non-proﬁt clone repository
AddGene (www.addgene.org). To complement our
method and reagents, we have also made our software
for TALEN site selection and design freely accessible as
an online tool, the TAL Effector Nucleotide Targeter at
http://boglabx.plp.iastate.edu/TALENT/. Although our
success rate was high with TALENs designed using the
software, we have not shown that it is ‘necessary’ to
follow the guidelines on which the software is based. So,
even though the guidelines place only relatively minor
constraints on targeting, the online tool allows users to
exclude them individually to increase candidate target
site frequency. Also, because optimal spacing may differ
for different TALEN architectures, the software provides
the option to specify desired spacer lengths. In making
these resources available, we hope to facilitate further
characterization of TAL effector DNA targeting
properties, broad adoption of TALENs and other TAL
effector-based tools and further development of the utility
of these unique DNA binding proteins.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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